1233689-64-9

Basic information

• Product Name: 3-Iodo-iMidazo[1,2-a]pyrazine
• Synonyms: 3-Iodo-iMidazo[1,2-a]pyrazine;Imidazo[1,2-a]pyrazine,3-iodo-
• CAS NO: 1233689-64-9
• Molecular Formula: C6H4IN3
• Molecular Weight: 245.02053
• Mol File: 1233689-64-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Iodo-iMidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Iodo-iMidazo[1,2-a]pyrazine(1233689-64-9)
• EPA Substance Registry System: 3-Iodo-iMidazo[1,2-a]pyrazine(1233689-64-9)

Safety Data

• Hazardous Substances Data: 1233689-64-9(Hazardous Substances Data)

Usage

General Description

3-Iodo-iMidazo[1,2-a]pyrazine is a chemical compound with the molecular formula C6H4IN3. It exists as a white to off-white solid and is used in pharmaceutical and chemical research as a building block for the synthesis of various organic compounds. 3-Iodo-iMidazo[1,2-a]pyrazine is known for its ability to act as a versatile intermediate in the production of biologically active molecules and pharmaceutical drugs. Its structure consists of a pyrazine ring fused with an imidazole ring, and the presence of an iodine atom on the imidazole ring makes it useful for further chemical reactions and modifications. 3-Iodo-iMidazo[1,2-a]pyrazine is commonly used in medicinal and agrochemical research as a key component in drug development and discovery.

Upstream product

• 274-79-3 imidazo[1,2-a]pyrazine 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.